Page last updated: 2024-11-12

lm11a-31

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

LM11A-31: a p75 neurotrophin receptor ligand; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID18604758
SCHEMBL ID1723692
MeSH IDM0577303

Synonyms (16)

Synonym
1243259-19-9
YNMUTYLWSRFTPX-QWRGUYRKSA-N
(2s,3s)-2-amino-3-methyl-n-(2-morpholinoethyl)-pentanamide
SCHEMBL1723692
lm11a-31
n-[2-(morpholin-4-yl)ethyl]-l-isoleucinamide
DTXSID50595097
(2s,3s)-2-amino-3-methyl-n-(2-morpholinoethyl) pentanamide
(2s,3s)-2-amino-3-methyl-n-(2-morpholinoethyl)pentanamide
102562-74-3
(2s,3s)-2-amino-3-methyl-n-(2-morpholin-4-ylethyl)pentanamide
BS-51733
F74058
lm-11a-31
pentanamide, 2-amino-3-methyl-n-[2-(4-morpholinyl)ethyl]-, (2s,3s)-
Y9GUF3B7Q7

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" Using this model and primary neuronal culture, we determined whether LM11A-31, a small-molecule, orally bioavailable ligand of the p75 neurotrophin receptor (p75(NTR)), can modulate Rho GTPase signaling and reduce CIPN."( Amelioration of cisplatin-induced experimental peripheral neuropathy by a small molecule targeting p75 NTR.
Duenas, M; Friesland, A; Longo, FM; Lu, Q; Massa, SM; Weng, Z, 2014
)
0.64

Dosage Studied

ExcerptRelevanceReference
" First, hollow cGEL tubes were fabricated by a continuous dosing and templating process."( Dual-Component Gelatinous Peptide/Reactive Oligomer Formulations as Conduit Material and Luminal Filler for Peripheral Nerve Regeneration.
Bhatnagar, D; Franz, S; Hacker, MC; Kaplan, HM; Kohn, J; Kohn-Polster, C; Richtmyer, M; Schulz-Siegmund, M; Springwald, AH; Starke, A; Woloszyn, DJ, 2017
)
0.46
" Future studies will assess the optimal dosing and duration of the compound."( Oral Administration of the p75 Neurotrophin Receptor Modulator, LM11A-31, Improves Erectile Function in a Mouse Model of Cavernous Nerve Injury.
Hong, SS; Limanjaya, A; Longo, FM; Minh, NN; Ock, J; Ryu, JK; Suh, JK; Yang, T; Yin, GN, 2021
)
0.86
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (23)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (4.35)29.6817
2010's14 (60.87)24.3611
2020's8 (34.78)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 31.48

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index31.48 (24.57)
Research Supply Index3.22 (2.92)
Research Growth Index6.11 (4.65)
Search Engine Demand Index35.70 (26.88)
Search Engine Supply Index2.13 (0.95)

This Compound (31.48)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other24 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]